Course InformationTherapautic Area: Cardiology
Format(s): Post Conference Review and Analysis
Credit(s): 1.0 AMA PRA Category 1 Credit™; 1.0 CME/CNE contact hour
Activity Dates: July 24, 2018 - July 23, 2019
This continuing education activity will review optimal treatment strategies and recent clinical trial data for patients who require emergent reversal of their direct oral anticoagulant therapy as presented at the American College of Cardiology 2018 in Orlando, Florida. Three expert faculty will analyze clinical profiles of reversal agents and current strategies to treat direct oral anticoagulant associated bleeds in emergent situations. Recent clinical trial data, as presented at ACC 2018 for the reversal of anticoagulation in Factor Xa, will be reviewed. The faculty will discuss best practices on how to apply recent evidence-based science to individualized treatment strategies to improve outcomes in patients who require emergent reversal of their direct oral anticoagulant therapy.
Cardiologists, primary care physicians, internists, nurse practitioners, nurses, and other healthcare providers involved in the management of patients with an acute major bleed associated with direct oral anticoagulants
1. Identify clinical profiles of reversal agents and current strategies to treat direct oral anticoagulant associated bleeds in emergent situations
2. Analyze clinical trial data as presented at ACC 2018 for the reversal of anticoagulation in Factor Xa
3. Apply recent evidence-based science to individualized treatment strategies to improve outcomes in patients who require emergent reversal of their direct oral anticoagulant therapy
Charles V. Pollack, Jr., MA, MD (Course Chair)
Professor of Emergency Medicine
Thomas Jefferson University
Director, Jefferson Institute of Emerging Health Professions
Director, The Lambert Center for the Study of Medicinal Cannabis and Hemp
Disclosures of Conflict of Interest
It is the policy of AcademicCME that all faculty, instructors, and planners disclose real or apparent conflicts of interest relating to the topics of this educational activity.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CNE activity:
|Faculty||Relationship Identified With:|
|Charles V. Pollack, Jr., MA, MD||Consultant/Advisor: AstraZeneca; Bristol-Myers Squibb; Boehringer Ingelheim; CSL Behring; Janssen Global Services, LLC; Pfizer Inc.; Portola Pharmaceuticals, Inc.Grant/Research Support: AstraZeneca; Boehringer Ingelheim; Daiichi Sankyo Company, Limited; Janssen Global Services, LLC; Portola Pharmaceuticals, Inc.|
|John Fanikos, RPh, MBA||Consultant/Advisor: Boehringer Ingelheim; Genentech, Inc.; Portola Pharmaceuticals, Inc.|
|Geno Merli, MD||Grant/Research Support: Biogen; Pfizer Inc.|
Planners, Managers, Reviewers
Timothy Hayes, MD, PhD; Emma Boring; Chelsey Benedek and Kim Cheramie, MSN, RN-BC hereby state that they or their spouse/life partner do not have any financial relationships to products or devices with any commercial interests related to the content of this activity of any amount during the past 12 months.
AcademicCME is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
AcademicCME is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.
Credit Designation Statement
AcademicCME designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
AcademicCME designates this enduring material for a maximum of 1.0 CNE contact hour.
This activity has been supported by an independent educational grant from Portola Pharmaceuticals, Inc.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. AcademicCME and Portola Pharmaceuticals, Inc. do not recommend the use of any agent outside of the labeled indications.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Method of Participation
1. Read the learning objectives, accreditation information and faculty disclosures at the beginning of this activity.
2. Complete the Pre-Activity Questions.
3. Read or Review the activity content.
4. Complete the Post-Activity Test Questions and Evaluation.
5. Healthcare providers who receive a grade of 70% or better on the Post-Activity Test Questions and who complete the Evaluation will receive a CME/CNE Certificate.
6. All other participants who receive a grade of 70% or better on the Post-Activity Test Questions and who complete the Evaluation will receive a Certificate of Participation.
7. Healthcare providers should claim only the credit commensurate with the extent of their participation in the activity.
8. 60 minutes of participation = 1 CNE contact hour
CE Inquiries/Special Needs
For all CME/CNE inquiries or special needs, please contact email@example.com.